International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 97

Review Papers | Hematology | Macedonia | Volume 4 Issue 11, November 2015


Is There Improvement in the Care for Patients With Multiple Myeloma?

Svetlana Stankovikj [4] | Kata Martinova [4] | Vera Stankovikj [3]


Abstract: Improved understanding of the multiple myeloma biology along with the discovery of novel anti-myeloma agents has led to a better-quality treatment of these patients. Multiple myeloma can cause a variety of complications such as hyperviscosity syndrome, hypercalcaemia, spinal cord compression, early infection, bone disease and renal impairment, some of which are life-treatening. Treatment of these has been demonstrated to significantly reduce morbidity and early fatal outcome. Utilization of novel agents including Thalidomide, Bortezomib and Lenalidomide as part of the induction protocols before autologous stem cell transplantation (ASCT) and also as a front-line treatment in older patients, has been shown to be superior in comparison with the previous treatment strategies. The latter has been confirmed regarding the overall treatment response, progression-free survival and even better overall survival in some studies. Greater experience in dosing of these medications has led to a decrease in the toxicity of the protocols. A third phase clinical study has demonstrated a better clinical outcome when Bortezomib was used prior ASCT. Furthermore, involvement of these agents in the post-transplant consolidation and maintenance treatments has been shown to be beneficial in other aspects such as prolongation of progression-free survival. The immune therapy represents a potentially promising treatment modality. Daratumumab is a new, specific, human monoclonal antibody with high affinity to a unique epitope on CD38. It induces plasma cells death through several immunological mechanisms. It has a good safety profile and a substantially activity as a single-agent therapy in refractory and relapsed myeloma.


Keywords: multiple myeloma, ASCT, Bortezomib, Thalidomide, Daratumumam


Edition: Volume 4 Issue 11, November 2015,


Pages: 1403 - 1406


How to Download this Article?

You Need to Register Your Email Address Before You Can Download the Article PDF


How to Cite this Article?

Svetlana Stankovikj, Kata Martinova, Vera Stankovikj, "Is There Improvement in the Care for Patients With Multiple Myeloma?", International Journal of Science and Research (IJSR), Volume 4 Issue 11, November 2015, pp. 1403-1406, https://www.ijsr.net/get_abstract.php?paper_id=NOV151442

Similar Articles with Keyword 'multiple myeloma'

Downloads: 3 | Weekly Hits: ⮙1 | Monthly Hits: ⮙3

Case Studies, Hematology, India, Volume 13 Issue 2, February 2024

Pages: 1654 - 1655

Waldenstroms Macroglobulinemia with Amyloid Cardiomyopathy - A Case Report

Dr. Mohammed Shanil P | Dr. Farsana Jasmin K

Share this Article

Downloads: 134

Research Paper, Hematology, Saudi Arabia, Volume 6 Issue 2, February 2017

Pages: 165 - 169

The Outcome of Autologous Stem Cell Transplantation: A Single Center Early Experience

Ahmed S. Alaskar | Khaled Alabduljabbar | Abdulellah Aladel | Sultan Aleshaiwi | Maissa Saade | Mohsen Alzahrani | Ayman Alhejazi | Khadeja Ahmed | Dunia Jawdat

Share this Article
Top